IRAK4 and myelodysplastic syndrome: IRAK4 inhibition led to reduced MDS clones in secondary transplants, demonstrating decrease in disease initiating activity (Figure 5G and H, Figure 5—figure supplement 3, summarized in Figure 5—figure supplement 4).